Goldman Sachs hosted a meeting with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (effective ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.

Despite Pfizer's (NYSE: PFE) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug ...

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United ...

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Is the healthcare stock in big trouble and headed for a greater decline, or are investors perhaps a bit too bearish on the ...

The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...

No financial details of the collaborations were released. However, Pfizer and Flagship committed $50 million each for the ...